Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy.
In the last years, the availability in Italy of technologically advanced products for replacement therapy has produced significant changes in the management of haemophilia and of hereditary bleeding disorders in general. With the aim of a uniform approach to treatment, the Italian Association of Haemophilia Centres express in these guidelines a consensus on therapeutic strategies designed to ensure the highest degree of safety and efficacy for the treatment of inherited coagulopathies. The guidelines provide specific recommendations for the choice of the product according to updated scientific evidence, and advice on optimal dosages for the treatment of rare bleeding disorders. The system for haemophilia care and funding in Italy is briefly described.
Santagostino
E
E
Via Pace 9, 20122 Milano, Italy.
Mannucci
P M
PM
Bianchi Bonomi
A
A
D001778:Blood Coagulation Disorders / Q000188:drug therapy* / Q000235:genetics; D001779:Blood Coagulation Factors / Q000592:standards / Q000627:therapeutic use*; D019468:Disease Management; D005192:Family Health; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D002836:Hemophilia B / Q000188:drug therapy / Q000276:immunology / Q000821:virology; D006801:Humans; D007558:Italy; D017410:Practice Guidelines as Topic
D001779:Blood Coagulation Factors